DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1751)

Emerging Vaccines | Landscape & Forecast | Disease Landscape & Forecast

Emerging Vaccines | Landscape & Forecast | Disease Landscape & Forecast

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Implementation of vaccination programs has had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult mortality and drastically improving the quality of life worldwide. Individuals can receive a wide range of vaccinations throughout their life that prevent infections and the diseases associated with chronic infections. Although vaccination guidelines may offer strong recommendations for certain vaccines, others are administered at the discretion of the prescribing physician and patient. As such, commercial opportunity exists for vaccines that can offer meaningful advantages over current agents. Despite notable competition, both the adult and pediatric segments of the vaccines market remain attractive areas for the development of new prophylactic options.

QUESTIONS ANSWERED

  • What are the sizes of the populations eligible for key vaccination programs in the G7?
  • Who are the key decision-makers for vaccine purchasing and administration, and how does this role vary by geography?
  • What are the key drivers of brand preference in a given vaccine market?
  • For which pathogens is unmet need greatest for a new or improved vaccine? Which patient pools do experts indicate will be eligible for these vaccines?
  • How will the current vaccine pipeline fulfill areas of unmet need in the vaccine market?
  • How will key current and emerging vaccines perform commercially?

PRODUCT DESCRIPTION

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • November 2018
      • August 2018
      • June 2018
      • March 2018
    • Market Outlook
      • Key Findings
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Vaccines?
        • What Factors Are Constraining the Market for Vaccines?
      • Segment-Specific Trends
        • Human Papillomavirus Vaccines
        • Herpes Zoster Vaccines
        • Meningococcus Vaccines
        • Pneumococcus Vaccines
        • Seasonal Influenza Vaccines
        • Hepatitis B Virus Vaccines
        • Respiratory Syncytial Virus Vaccines
      • Alternative Market Scenarios
    • Forecast
    • Vaccine Technologies
      • Immunology and Vaccine-Preventable Diseases
      • Active Immunity
      • Classification of Vaccines
      • Live Attenuated Vaccines
      • Inactivated Vaccines
      • Polysaccharide Vaccines
      • Vaccines Based on Bacterial Proteins, Polysaccharides, and Protein-Conjugated Polysaccharides
      • Recombinant Vaccines
      • Adjuvants
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Respiratory Syncytial Virus Vaccine-Eligible Population
        • Hepatitis B Virus Vaccine-Eligible Population
        • Human Papilloma Virus Vaccine-Eligible Population
        • Shingles Vaccine-Eligible Population
        • Influenza Vaccine-Eligible Population
        • Pneumococcal Vaccine-Eligible Population
        • Meningococcal B Vaccine-Eligible Population
        • Meningococcal ACWY Vaccine-Eligible Population
        • Number of Vaccinated Cases
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Human Papillomavirus Vaccines
        • Pneumococcal Vaccines
        • Meningococcal Vaccines
        • Seasonal Influenza Vaccines
        • Hepatitis B Virus Vaccines
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs for Vaccines
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Vaccines
        • Seasonal Influenza Vaccines
        • Pneumococcal Vaccines
        • Respiratory Syncytial Virus Vaccines
        • Hepatitis B Virus Vaccines
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Vaccine Pipeline
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Vaccine-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • Agents Included in Our Market Analysis
        • General Statements About Pricing
        • Out-Year Forecasting
        • Emerging Vaccine Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Vaccines Bibliography

Already a Client? Log in to access this report.

  • Pub Date: November 2018
  • Author(s): Michael Breen, PhD; Alison Isherwood, MSc, MRes, PhD
  • Michael is a business insights analyst on the Infectious, Niche, and Rare Diseases team. He has authored reports on cystic fibrosis, nonalcoholic steatohepatitis, vaccines, and  respiratory syncytial virus, and will author a report on cytomegalovirus. He also provides coverage for Decision Resources’ Company & Drug Insights covering anti-infectives, vaccines, and transplant therapy areas. Michael received his Bachelor’s degree from Hunter College with a dual major in biology and biochemistry. He received his in biochemistry from Boston University School of Medicine. His postdoctoral research was carried out at Brigham and Women’s Hospital/Harvard Medical School, with a focus on identifying novel pathways regulating thermogenesis in search of a therapeutic for obesity and diabetes.

  • Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.

Purchase Report

Recent reports:
You may also be interested in: